Invent Medic Sweden (IMS) Q1 2025 earnings summary

Executive summary

• Net sales increased to 2,000 KSEK from 1,855 KSEK year-over-year, with improved pre-tax results at -1,400 KSEK versus -1,927 KSEK.

• February marked the strongest sales month ever, driven by a record order for Efemia Bladder Support from the UK distributor.

• Strengthened financial position with improved equity ratio and significantly lower debt-to-equity ratio compared to the previous year.

• New CEO Gunilla Nilsson appointed March 1, following interim CEO Helena Liljedahl.

Financial highlights

• Net sales for Q1 2025: 2,000 KSEK (up from 1,855 KSEK in Q1 2024).

• Pre-tax result: -1,400 KSEK (improved from -1,927 KSEK year-over-year).

• EPS: -0.02 SEK (improved from -0.05 SEK year-over-year).

• Cash and cash equivalents at period end: 594 KSEK (down from 1,208 KSEK year-over-year).

• Operating expenses reduced to -3,325 KSEK from -3,638 KSEK year-over-year.

Outlook and guidance

• Focus on expanding partnerships, especially in Germany and Spain, and continued growth in France.

• Ongoing efforts to secure new NGO collaborations and further increase sales to Swedish regions.

• Strategic goal of organic growth through product development, quality, marketing, and synergies across business areas.